medigraphic.com
Colegio de Medicina Interna de México.

2018, Número 5

<< Anterior Siguiente >>

Med Int Mex 2018; 34 (5)


Prescripción racional de antibióticos: una conducta urgente

Isaías-Camacho JO, Salinas-Lezama E, Rodríguez-Weber FL, Díaz-Greene E

Idioma: Español
Referencias bibliográficas: 36
Paginas: 762-770
Archivo PDF: 450.48 Kb.


RESUMEN

Los antibióticos han revolucionado la forma de ver y practicar la medicina. Gracias a su existencia millones de vidas se han salvado a lo largo de la historia. Sin embargo, en el siglo XXI surge un tema que es de vital importancia atender: la resistencia antimicrobiana. La resistencia antimicrobiana amenaza el futuro de lo que alguna vez fue cura de muchas enfermedades mortales y representa un reto actual para todo el profesional de la salud. La resistencia antimicrobiana no es un tema que haya surgido recientemente, pero la cantidad de resistencia a organismos, las ubicaciones geográficas afectadas por la resistencia a los medicamentos y la amplitud de la resistencia en organismos individuales están aumentando de forma acelerada. Existen más de 15 clases de antibióticos cuyos mecanismos de acción están implicados en funciones fisiológicas o metabólicas esenciales del microorganismo. De los anteriores, ninguno ha escapado de algún mecanismo de resistencia.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. OECD, Antimicrobial Resistance. [Online]. Available from: www.oecd.org/health/antimicrobial-resistance.htm [Accessed 24 Enero 2018].

  2. Levy S. The antibiotic paradox: How misuse of antibiotics destroys their curative powers. Clinical Infectious Diseases 2003;36(2).

  3. World Health Organization. [Online]. Available from: http:// www.who.int/mediacentre/factsheets/fs194/en/ [Accessed 24 Enero 2018].

  4. Marston H, et al. Antimicrobial resistance. JAMA 2016;316(11).

  5. Hoffman JM, et al. Projecting future drug expenditures 2007. Am J Health Syst Pharm 2007;64:298-314.

  6. Levy S, et al. Antibacterial resistance worldwide: causes, challenges and responses. Nature Medicine Supplement 2004;10(12).

  7. Levy SB. The challenge of antibiotic resistance. Sci Am 1998;278(3):46-53.

  8. Levy SB. Microbial resistance to antibiotics. An evolving and persistent problem. Lancet 1982;2:83-88.

  9. Barber M. Infection by penicillin resistant Staphylococci. Lancet 1948;2:641-644.

  10. Crofton J, et al. Streptomycin resistance in pulmonary tuberculosis. Br Med J 1948;2:1009-1015.

  11. Davey P, et al. Interventions to improve antibiotic prescribing practices for hospital inpatients. Cochrane Database Syst Rev 2013;4(CD003543).

  12. Centers for disease control and prevention, C.D.C [Online]. Available from: http://www.cdc.gov/drugresistance/ threat -report-2013/ [Accessed 24 January 2018].

  13. President’s council of advisors on science and technology. Report to the President on combating antibiotic resistance. [Online]. Available from: https://www.whitehouse. gov /sites/default/files/microsites/ostp/PCAST/pcast _amr_jan2015.pdf. [Accessed 24 January 2018].

  14. O’neill JIM. Antimicrobial Resistance: Tackling a crisis for the health and wealth of nations. Rev Antimicrob Resistance 2014;1.

  15. Arias C, Murray, B. A New antibiotic and the evolution of resistance. NEJM 2015;372(12).

  16. Suda KJ, et al. A national evaluation of antibiotic expenditures by healthcare setting in the United States, 2009. J Antimicrob Chemother 2013;68(3):715-718.

  17. Fleming-Dutra KE, Hersh AL, Shapiro DJ, et al. Prevalence of inappropriate antibiotic prescriptions among US ambulatory care visits, 2010-2011. JAMA 2016;315(17):1864-1873.

  18. Morgan DJ, et al. Non-prescription antimicrobial use worldwide: a systematic review. Lancet Infect Dis 2011;11(9):692-701.

  19. Levy SB. Balancing the drug resistance equation. Trends Microbiol 1994;2:341-342.

  20. Levy SB. The 2000 Garrod lecture. Factors impacting on the problem of antibiotic resistance. J Antimicrob Chemother 2002;49:25-30.

  21. Pray L. Antibiotic resistance, mutation rates and MRSA. Nature Educ 2008;1(1):30.

  22. Levy SB. Active efflux mechanisms for antimicrobial resistance. Antimicrob Agents Chemother 1992;36:695-703.

  23. Nikaido H. Multidrug efflux pumps of gram-negative bacteria. J Bacteriol 1996:178: 5853-5859.

  24. Paterson DL, et al. International prospective study of Klebsiella pneumoniae bacteremia: implications of extendedspectrum β-lactamase production in nosocomial Infections. Ann Intern Med 2004;140:26-32.

  25. Nordmann, P. Poirel, L. Emerging carbapenemases in Gramnegative aerobes. Clin Microbiol Infect 2002;8:321-331.

  26. Wang H, et al. Genetic characterization of highly fluoroquinolone- resistant clinical Escherichia coli strains from China: role of acrR mutations. Antimicrob Agents Chemother 2001;45:1515-1521.

  27. Ben-David D, et al. Outcome of carbapenem-resistant Klebsiella pneumoniae bloodstream infections. Clin Microbiol Infect. 2012;18(1):54-60.

  28. Snitkin ES, et al; NISC Comparative Sequencing Program Group. Tracking a hospital outbreak of carbapenemresistant Klebsiella pneumoniae with whole-genome sequencing. Sci Transl Med 2012;4(148).

  29. Liu YY, et al. Emergence of plasmid-mediated colistin resistance mechanism mcr-1 in animals and human beings in China: a microbiological and molecular biological study. Lancet Infect Dis 2016;16(2):161-168.

  30. McDonald LC, et al. An epidemic, toxin gene-variant strain of Clostridium difficile. N Engl J Med 2005;353(23):2433- 2441.

  31. Magill SS, et al; Emerging Infections ProgramHealthcare- Associated Infections and Antimicrobial Use Prevalence Survey Team. Multistate point prevalence survey of health care-associated infections. N Engl J Med 2014;370 (13):1198-1208.

  32. Schuetz P, et al. Procalcitonin to initiate or discontinue antibiotics in acute respiratory tract infections. Cochrane Database Syst Rev 2012;(9):CD007498.

  33. Sager R, et al. Procalcitonin-guided diagnosis and antibiotic stewardship revisited. BMC Medicine 2017;15:15.

  34. Nathwani D, Sneddon J. Practical guide to antimicrobial stewardship in hospitals. [Online]. Available from: http:// bsac.org.uk/wp-content/uploads/2013/07/Stewardship- Booklet-Practical-Guide-to-Antimicrobial-Stewardship-in- Hospitals.pdf . [Accessed 24 Enero 2018].

  35. Barbosa TM, et al. The impact of antibiotic use on resistance development and persistence. Drug Resist Updat 2000;3:303-311.

  36. Sandberg T, et al. Ciprofloxacin for 7 days versus 14 days in women with acute pyelonephritis: a randomised, openlabel and double-blind, placebo-controlled, non-inferiority trial. Lancet 2012;358:484-90.




2020     |     www.medigraphic.com